SOURCE-LINKED STUDY SUMMARY
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
Abstract summarizedQuality not appraised
- What was studied
- Randomized phase 2 trial tested survodutide for biopsy-assessed MASH improvement without worsening liver fibrosis.
- Who / model studied
- 293 treated adults with biopsy-confirmed MASH and fibrosis stages F1–F3.
- Studied dose & schedule
- Survodutide 2.4, 4.8 or 6.0 mg subcutaneously once weekly versus placebo for 48 weeks: 24-week escalation followed by 24-week maintenance.
- What the study found
- MASH improvement without fibrosis worsening: 47%, 62%, 43% versus 14% placebo, respectively. Fibrosis improved ≥1 stage in 34%, 36%, 34% versus 22%. Across survodutide groups, nausea affected 66% versus 23%; vomiting 41% versus 4%. Serious adverse events: 8% versus 7%.
- Limitations & context
- Abstract assessment. Biopsy endpoints do not establish fewer liver complications or deaths; phase 3 confirmation remains necessary. No active-drug comparator was tested.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2401755